Agenix cuts COO position
Thursday, 27 October, 2005
Brad Calvin is to step down as chief operating officer of Agenix (ASX:AGX) today after the company decided not to renew his employment contract.
Agenix managing director Donald Home will take on Calvin's responsibilities.
The company said Calvin was initially employed to lead the sales and marketing of the Agenix's Animal Health, Human Health and Milton Pharmaceuticals businesses and to assist in the commercialisation of the company's ThromboView product.
Agenix has since divested Milton Pharmaceuticals and entered into an agreement for the global sales, marketing and distribution of ThromboView and the company decided that its requirements for the Animal and Human Health businesses "did not warrant the current level of staffing".
Lipid science receives new Australia-led online hub
The Lipid Network launched this month to build links between researchers, clinicians and industry...
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
